NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLCStrategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion AnimalsCompany targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies.
